Literature DB >> 22440861

Sebaceous glands as the primary target of EGFR-inhibitors in the development of papulopustular eruption.

Tomoya Takata, Masahito Tarutani, Christos C Zouboulis, Shigetoshi Sano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22440861     DOI： 10.1016/j.jdermsci.2012.02.012

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN： 0923-1811            Impact factor:   4.563


× No keyword cloud information.
  6 in total

1.  Analysis of sebum lipid composition and the development of acneiform rash before and after administration of egfr inhibitor.

Authors:  T Nakahara; Y Moroi; K Takayama; Y Nakanishi; M Furue
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors.

Authors:  Takeshi Nakahara; Yoichi Moroi; Koichi Takayama; Eriko Itoh; Makiko Kido-Nakahara; Yoichi Nakanishi; Masutaka Furue
Journal:  Onco Targets Ther       Date:  2015-01-28       Impact factor: 4.147

3.  CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.

Authors:  Tomasz Jarząbek; Monika Rucińska; Wojciech Rogowski; Marzena Lewandowska; Jerzy Tujakowski; Maja Habib; Anna Kowalczyk; Agnieszka Byszek; Rafał Dziadziuszko; Sergiusz Nawrocki
Journal:  Mol Diagn Ther       Date:  2015-04       Impact factor: 4.074

4.  In Vivo Fluorescence Immunohistochemistry: Localization of Fluorescently Labeled Cetuximab in Squamous Cell Carcinomas.

Authors:  Esther de Boer; Jason M Warram; Matthew D Tucker; Yolanda E Hartman; Lindsay S Moore; Johannes S de Jong; Thomas K Chung; Melissa L Korb; Kurt R Zinn; Gooitzen M van Dam; Eben L Rosenthal; Margaret S Brandwein-Gensler
Journal:  Sci Rep       Date:  2015-06-29       Impact factor: 4.379

5.  Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.

Authors:  Eric Assenat; David Azria; Caroline Mollevi; Rosine Guimbaud; Nicole Tubiana-Mathieu; Denis Smith; Jean-Pierre Delord; Emmanuelle Samalin; Fabienne Portales; Christel Larbouret; Bruno Robert; Frédéric Bibeau; Jean-Pierre Bleuse; Evelyne Crapez; Marc Ychou; André Pèlegrin
Journal:  Oncotarget       Date:  2015-05-20

6.  Local cortisol activation is involved in EGF-induced immunosuppression.

Authors:  Sayaka Matsumura; Mika Terao; Satoshi Itami; Ichiro Katayama
Journal:  Dermatoendocrinol       Date:  2017-12-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.